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Abstract
Introduction: Chronic back pain (CBP) is frequently the presenting symptom in patients with suspected axial
spondyloarthritis (axSpA). Presence of sacroiliitis on magnetic-resonance-imaging (MRI) or HLA-B27 adds to
diagnostic certainty. However, these costly tests cannot be applied in all patients with CBP. This study aims to
investigate which SpA features increase the likelihood of a positive HLA-B27 or positive MRI of the sacroiliac-joints
(MRI-SI) in patients with suspected axSpA.
Methods: Data from 665 patients with CBP within the ESPeranza Programme were analysed. Diagnostic utility
measures (LR+, LR−) for a positive MRI-SI or HLA-B27 were calculated for various definitions of inflammatory back
pain (IBP), their separate items and for other SpA features.
Results: Pretest probabilityies of a positive result was 41 % for MRI-SI and 40 % for HLA-B27. For a positive MRI-SI
result the most useful IBP characteristic was alternating buttock pain (LR + =2.6). Among the IBP-criteria, fulfillment
of the ‘ASAS criteria’ (LR + =2.1) was most contributory. Interestingly, the addition of alternating buttock pain to the
Calin/ASAS-IBP criteria (LR + =6.0 and 5.5, respectively) or the addition of awakening at second half of night to the
Calin-IBP criteria (LR + =5.5) increased the pre-test probability of MRI-sacroiliitis from 41 % to 79–80 %. Dactylitis
(LR + =4.1) and inflammatory bowel disease (IBD) (LR + =6.4) increased this probability to 73 % and 81 %, respectively.
To forecast HLA-B27 positivity, awakening at the second half of the night, fulfillment of the ASAS-IBP definition and
uveitis were the most useful, but only marginally predictive (LR + = 1.3, 1,6 and 2.6, respectively).
Conclusions: If patients with suspected axial SpA have either 1) IBP according to Calin/ASAS definition plus alternating
buttock pain, or 2) IBP according to Calin definition plus awakening at night, or 3) dactylitis or 4) IBD, the probability of
finding a positive MRI-SI increases significantly.
* Correspondence: mvictoria.navarroc@gmail.com
1Department of Rheumatology, IdiPaz, University Hospital La Paz, Madrid, Spain
2Department of Rheumatology, Leiden University Medical Center, Leiden,
The Netherlands
Full list of author information is available at the end of the article
© 2015 Navarro-Compán et al. Open Access This article is distributed under the terms of the Creative Commons Attribution
4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Navarro-Compán et al. Arthritis Research & Therapy  (2015) 17:265 
DOI 10.1186/s13075-015-0779-y
Introduction
Axial spondyloarthritis (axSpA) has a major impact on
physical function and quality of life [1]. Nevertheless, des-
pite these important consequences patients with axSpA
have been traditionally diagnosed after several years of
symptoms [2]. In this sense, magnetic resonance imaging
of sacroiliac joints (MRI-SI) has become important in the
last decade, especially in the early stages of the disease.
Nowadays, performing imaging, and testing human leuco-
cyte antigen B27 (HLA-B27) are among the most import-
ant diagnostic procedures in patients with (suspicion of)
axSpA. Accordingly, imaging and HLA-B27 results are
also the entry criterion for classifying patients with
chronic back pain (CBP) as having axSpA based on the
classification criteria of the Assessment of SpondyloAr-
thritis International Society (ASAS) [3].
Furthermore, in patients with suspected axSpA the
starting point of the disease is usually the presence of
CBP. However, CBP is one of the most prevalent symp-
toms in the general population and therefore it is essential
to be able to select which patients with CBP have the
highest chance of being diagnosed with axSpA. For this
purpose, several referral strategies including different
manifestations at the beginning of the disease have been
developed for primary physicians, but [4–6] in clinical
practice most patients are referred from primary care to
rheumatologists because of inflammatory back pain (IBP)
[4]. However, despite the publication of several IBP defini-
tions [7–9], there is only poor agreement between primary
physicians and rheumatologists about the presence of IBP.
In addition to this, the original algorithm for diagnosing
axSpA has been recently modified, excluding IBP as an
obligatory entry criterion. This modification has been ap-
plied based on the finding that up to 30 % of patients with
axSpA do not have IBP, and therefore its inclusion as an
obligatory entry criterion results in too many misdiag-
noses [10]. According to the modified algorithm, comple-
mentary examinations (HLA-B27 and MRI) need to be
considered in those patients without sacroiliitis on con-
ventional x-rays or with fewer than four featuresof SpA,
which usually comprises most of the referred patients. But
in clinical practice, due to efficiency reasons these tests
must usually be restricted to patients with higher prob-
ability of a positive result. Based on clinical features, it
would be very helpful for rheumatologists to identify
which referred patients have the highest likelihood of ul-
timately being diagnosed as having axSpA. Such features
of SpA that can be obtained by taking history or by simple
physical examination, could potentially contribute to an
efficient test-sequence to be applied in patients presenting
with CBP and to optimise the use of supplementary tests
in these patients. Based on this, this study aims to investi-
gate which features of SpA may increase the pre-test
probability of a positive test result of HLA-B27 or MRI-SI
in patients with suspected axSpA, which is a step forward
in making a diagnosis of axSpA.
Methods
Study design and population
This study was performed within the context of the
ESPeranza Programme. The details from this initiative
have been previously reported [11–13]. In summary, the
ESPeranza Programme is a Spanish prospective multi-
centre national health programme aiming to facilitate
early diagnosis of patients with spondyloarthritis. The
programme was designed in compliance with the Helsinki
Declaration and approved by the Ethical Committee of
Research Unit of Hospital Reina Sofía in Córdoba. Over
3 years from April 2008, primary physicians and other
specialists were asked by rheumatologists to refer patients
meeting the following criteria: 1) age from 18 to 45 years;
2) symptom duration between 3 and 24 months; and 3)
fulfilling one of the following three symptoms: IBP, asym-
metrical arthritis or spinal/joint pain plus the presence of
at least one of the following features: psoriasis, inflamma-
tory bowel disease (IBD), anterior uveitis, radiographic
sacroiliitis, HLA-B27 positivity, or a family history of
spondylitis. All patients provided signed informed con-
sent. In total, 25 centres across the country participated in
the programme and 775 patients met the inclusion cri-
teria. For the current study, only those patients referred
with axial symptoms (n = 665) were selected.
Data collection and clinical measures
In the ESPeranza programme, sociodemographic and
disease data were collected including age, sex, symptom
duration, family history of SpA or related diseases, periph-
eral manifestations (enthesitis, dactylitis and/or arthritis)
and extra-articular manifestations (psoriasis, uveitis, IBD).
In addition, all typical characteristics of IBP were separ-
ately collected including: morning stiffness, improvement
of back pain with exercise and not with rest, alternating
buttock pain, insidious onset and awakening during the
second half of the night. Moreover, the SpA feature related
with CBP and CBP, “Good response to nonsteroidal anti-
inflammatory drugs (NSAIDs)” were collected too. Based
on this information, the fulfilment of the different
existing IBP criteria was established as follows: Calin
(at least four out of the following five criteria: age
<40 years, insidious onset, duration >3 months, morning
stiffness, improvement with exercise); Berlin (at least two
out of the following four: morning stiffness, improvement
with exercise and not with rest, awakening during the sec-
ond half of the night, alternating buttock pain) and ASAS
(at least four out of the following five: age <40 years, insidi-
ous onset, improvement with exercise, no improvement
with rest, night pain).
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Clinical assessments were also performed, including
disease activity (Bath ankylosing spondylitis disease activ-
ity index, BASDAI), function (Bath ankylosing spondylitis
functional index, BASFI), and laboratory tests (C-reactive
protein (CRP)). The presence of HLA-B27 was tested in
the local laboratory of each centre according to the stand-
ard procedure. The evaluation of conventional radio-
graphs of the cervical and lumbar spine and of the pelvis
was part of the protocol. MRI-SI was not included in the
protocol as mandatory. Nevertheless, all rheumatologists
were asked to perform MRI-SI if possible. However, due
to existing differences between centres in accessibility to
MRI, including budget limitations and waiting lists for
MRI, MRI-SI was not performed all patients. MRI-SI was
evaluated locally by one reader at each hospital, who eval-
uated the presence or absence of sacroiliitis according to
the ASAS definition [14].
Statistical analysis
For descriptive purpose, results for continuous variables
are presented as mean and standard deviation (SD) and
for categorical variables are shown as percentage and rela-
tive frequencies. The diagnostic utility of each IBP charac-
teristic, good response to NSAIDs, IBP definitions (Calin,
Berlin, ASAS) and other features of SpA for a positive
MRI-SI or HLA-B27 was calculated. Diagnostic utility was
assessed based on sensitivity, specificity, positive and
negative predictive values (PPV and NPV) and especially,
positive and negative likelihood (LR+ and LR−). Import-
antly, a cutoff value of 4.0 was used for LR+ to define a
feature of SpA as useful. The reason for the selection of
this cutoff is that it has been associated with a moderate
increase (approximately 25 %) in the likelihood of disease
[15]. Finally, post-test probability was calculated based on
the positive and negative likelihood ratios using the fol-
lowing conversion formula:
Odds = Probability/(1 – Probability).
According to Bayes’ law (post-test odds = pre-test odds*
LR, in which LR– is used if a feature is absent and the
LR+ if a feature is present) the likelihood of finding a
positive MRI/HLAB27 was estimated in patients with
this particular feature present or absent.
Results
Baseline characteristics
A total of 665 patients with axial symptoms were re-
ferred and included in ESPeranza. Fifty five percent were
male, mean (SD) age was 33.2 (7.1) years and mean (SD)
symptom duration was 12.6 (6.6) months. For most of
them (n = 653; 98.2 %) data was also available on HLA-
B27 testing, and these were included in the analysis to
evaluate the association between IBP characteristics and
the presence of HLA-B27. Approximately half of the pa-
tients (n = 326; 49 %) had MRI-SI performed and were
included in the analysis to investigate the association be-
tween IBP characteristics and positive MRI-SI. Demo-
graphic and disease characteristics were similar for patients
in the whole cohort compared with patients in whom
MRI-SI had been performed (Table 1). In total, 270 (41 %)
patients were HLA-B27 positive and 130 (40 %) patients
had a positive MRI-SI result (pre-test probabilities).
Table 1 Baseline characteristics for all patients with axial
symptoms included in Esperanza (left column) and for the
subgroup of patients who underwent MRI-SI (right column)
Characteristic Patients with axial
symptoms referred
to Esperanza (n = 665)
Patients with axial
symptoms and SIJ
MRI available (n = 326)
Age, years 33.2 ± 7.1 32.8 ± 7.0
Male 363 (54.6) 175 (53.7)
Symptoms duration,
months
11.9 ± 6.6 12.6 ± 6.4
Morning stiffness 393 (59.1) 195 (59.8)
Improve with exercise,
not with rest
208 (31.3) 97 (29.8)
Alternating buttock pain 197 (29.6) 98 (30.1)
Insidious onset 430 (64.7) 256 (78.5)
Awakening at second
half of night
315 (47.4) 169 (51.8)
Response to NSAIDs 407 (61.2) 200 (61.3)
Enthesitis 107 (16.1) 45 (13.8)
Psoriasis 82 (12.3) 35 (10.7)
Dactylitis 26 (3.9) 14 (4.3)
IBD 26 (3.9) 10 (3.1)
Uveitis 34 (5.1) 16 (4.9)
Arthritis 95 (14.3) 37 (11.3)
Family history 170 (25.6) 89 (27.3)
HLA-B27 270 (40.6) 144 (44.2)
Elevated CRP, mg/L 177 (26.6) 89 (27.3)
BASDAI 4.0 ± 2.3 3.9 ± 2.3
BASFI 2.5 ± 2.4 2.3 ± 2.4
ASAS criteria for axial
SpA
291 (43.8) 167 (51.2)
Imaging arm 194 (29.2) 132 (40.5)
MRI-SI positive 85 (12.8) 85 (26.1)
mNY-positivea 109 (16.4) 47 (14.4)
Clinical arm only 97 (14.6) 35 (10.7)
Results are presented as mean ± SD or number (%). aPatients who were both
magnetic resonance imaging of sacroiliac joints (MRI-SI)-positive and modified
New York criteria for ankylosing spondylitis (mNY)-positive) are included.
NSAIDs nonsteroidal anti-inflammatory drugs, IBD inflammatory bowel disease,
HLA-B27 human leucocyte antigen B27, CRP C-reactive protein, BASDAI Bath
ankylosing spondylitis disease activity index, BASFI Bath ankylosing spondylitis
functional index, ASAS Assessment of SpondyloArthritis International Society,
SpA spondyloarthritis
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IBP characteristics forecasting the presence of sacroiliitis
on MRI or HLA-B27
Table 2 shows the results for the diagnostic utility of
these characteristics. While alternating buttock pain was
most contributory in predicting a positive MRI-SI result
(LR + = 2.6; LR − = 0.6), awakening during the second half
of the night was the most contributory in predicting a
positive HLA-B27 result (LR+ =1.3; LR − = 0.8). However,
individually none of the characteristics made a very strong
contribution.
IBP definitions forecasting the presence of sacroiliitis on
MRI or HLA-B27
The three multi-item IBP definitions performed more or
less similarly in terms of a LR+. To forecast a positive
MRI-SI, the ASAS criteria performed slightly better but
still produced very low LRs (LR + = 2.1; LR − = 0.7)
(Table 3). Based on these results, it was decided to assess
whether or not the addition of other IBP characteristics
(or good response to NSAID) which were not included
in the definitions of IBP increased their diagnostic utility.
This means that patients had to fulfil the specific IBP def-
inition plus the additional characteristic. The results for
this analysis are depicted in Table 3. Of all possible combi-
nations, the ones that performed better were the combin-
ation of the Calin/ASAS definition and alternating buttock
pain (LR + = 6.0 and 5.5, respectively; LR − = 0.7 for both
combinations) and the combination of the Calin definition
and awakening in the second half of the night (LR + = 5.5;
LR − = 0.8). These combinations had a post-test probability
of sacroiliitis on MRI of 79–80 % if the combined criterion
was present, and 32–35 %, if the combined criterion was
absent.
Similar to sacroiliitis, the three IBP definitions performed
similarly well to predict a positive HLA-B27 result
(Table 3). The ASAS criteria performed best but the LR+
(1.6) and LR− (0.9) was poor. On the other hand, and in
contrast to the results for sacroiliitis, the addition of other
IBP characteristics (or good response to NSAIDs) to the
existing IBP definitions only slightly increased their diag-
nostic utility.
Other features of SpA forecasting the presence of
sacroiliitis on MRI or HLA-B27
The utility of features of SpA other than IBP in helping to
anticipate a positive (or a negative) MRI-SI or a positive
(or negative) HLA-B27 test result was also evaluated.
These SpA features included peripheral and extra-
articular manifestations, family history of SpA or related
diseases, elevated CRP and HLA-B27 (only for MRI-SI).
While dactylitis and IBD appeared to be the most useful
features of SpA for forecasting positive MRI-SI (LR + = 4.1
and 6.4, respectively), uveitis was the best for a positive
HLA-B27 test, but had a LR+ of only 2.6 (Table 3). The
presence or history of dactylitis or IBD resulted in a post-
test probability for positive MRI of 73 % and 81 %, re-
spectively, compared with the pre-test probability of 40 %.
The post-test probability decreased from 40 % to 35 % if
both dactylitis and IBD were confirmed absent.
Discussion
This study evaluates the utility of IBP characteristics,
separately and combined, as well as other features of
SpA to anticipate the presence of sacroiliitis on MRI or
a positive result in HLA-B27 testing in patients with sus-
pected axSpA.
In contrast to most prediction analyses, we have
adopted a Bayesian approach based on likelihood ratios,
rather than a ‘frequentist approach’ with odds ratios fo-
cusing on positive test results. The Bayesian approach is
far closer to clinical reality because it directly visualizes
the consequences of a positive test result (here, IBP cri-
teria present) and a negative test result (here, IBP criteria
absent) on the likelihood of the outcome (here, positive
MRI-SI result) in a cohort with a given prevalence of the
outcome. In contrast, the effects of odds ratios obtained
with regular regression analysis (either significant or
not) on the outcome of interest are entirely dependent
Table 2 Values for diagnostic utility measures for each of the inflammatory back pain characteristics in relation to the presence of
sacroiliitis on MRI, and positive HLA-B27 testing
Sacroiliitis on MRI HLA-B27
Sen Spe LR+ LR− PPV NPV Sen Spe LR+ LR− PPV NPV
Morning stiffness for >30 minutes 68.5 45.9 1.3 0.7 45.6 68.7 63.3 43.6 1.1 0.8 44.2 62.8
Improvement with exercise, not with rest 31.5 71.4 1.1 0.1 42.3 61.1 33.7 70.2 1.1 0.9 44.4 60.0
Alternating buttock pain 47.7 81.6 2.6 0.6 63.3 70.2 31.9 71.3 1.1 0.9 43.9 59.7
Insidious onset 87.7 27.6 1.2 0.4 44.5 77.1 68.1 37.1 1.1 0.9 43.3 62.3
Awakening in second half of the night 64.6 56.6 1.5 0.6 49.7 70.7 55.2 57.4 1.3 0.8 47.8 64.5
Response to NSAIDs 69.2 43.9 1.2 0.7 45.0 68.3 67.4 43.3 1.2 0.8 45.6 65.4
MRI magnetic resonance imaging, HLA-B27 human leucocyte antigen B27, Sen sensitivity, Spe specificity, LR+ positive likelihood ratio, LR− negative likelihood ratio,
PPV positive predictive value, NPV negative predictive value, NSAIDs nonsteroidal anti-inflammatory drugs
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on the prevalence of the outcome, and the clinical value
is difficult to disentangle (and often disappointingly low).
To predict the presence of sacroiliitis on MRI, we have
found that alternating buttock pain and the ASAS-
definition for IBP are the most useful characteristic and
criterion, respectively, but neither of them performed
sufficiently well when tested alone. Interestingly, the
addition of the criterion of alternating buttock pain to
the Calin or ASAS definition increased the positive like-
lihood ratio for MRI-SI notably compared to the Calin
or ASAS definition alone (LR+ 6.0 vs 1.8 respectively for
the Calin definition and 5.5 vs 2.1, respectively, for the
ASAS definition). When the Berlin algorithm had been
designed, the criterion of alternating buttock pain also
increased the specificity for axSpA but at the cost of a
very low sensitivity (because alternating buttock pain
was a rare finding) [16]. When the ASAS definition for
IBP was later developed, it therefore did not contribute
independently to the presence of IBP according to expert
opinion and therefore was not included in the proposed
definition [7]. In the current study, we decided to re-
examine the performance of the criterion of alternating
Table 3 Values for diagnostic utility measures for each of the inflammatory back pain definitions and other features of SpA in
relation to the presence of sacroiliitis on MRI and positive HLA-B27 testing
Sacroiliitis on MRI HLA-B27
Sen Spe LR+ LR− PPV NPV Sen Spe LR+ LR− PPV NPV
IBP definition
Calin criteria 51.5 70.9 1.8 0.7 54.0 68.8 36.3 74.2 1.4 0.9 49.7 62.3
Berlin criteria 72.3 50.5 1.5 0.6 49.2 73.3 64.1 49.3 1.3 0.7 47.1 66.1
ASAS criteria 47.7 77.0 2.1 0.7 57.9 68.9 31.5 80.7 1.6 0.9 53.5 62.3
IBP definition plus other IBP characteristics
Calin + alt. buttock 30.8 94.9 6.0 0.7 80.0 67.4 17.4 86.4 1.3 1.0 51.0 56.3
Calin + NSAIDs 36.2 80.1 1.8 0.8 54.7 65.4 28.5 75.7 1.2 0.9 48.8 56.5
Calin + night 28.0 94.9 5.5 0.8 77.8 67.4 16.2 87.9 1.3 1.0 52.3 56.3
Calin + alt. buttock + night 26.9 94.9 5.3 0.8 77.8 66.2 16.0 88.1 1.3 1.0 52.3 56.3
Calin + alt. buttock + NSAIDs 20.0 96.9 6.5 0.8 81.3 64.6 10.4 91.0 1.2 1.0 48.4 55.5
Calin + Night + NSAIDs 29.2 87.2 2.3 0.8 60.3 65.0 21.5 88.3 1.8 0.9 56.3 61.5
Berlin + Insidious 64.6 62.2 1.7 0.6 53.1 72.6 50.7 53.1 1.1 0.9 46.8 57.0
Berlin + NSAIDs 53.8 68.4 1.7 0.7 53.0 69.1 48.9 66.1 1.4 0.8 50.4 64.7
Berlin + insidious + NSAIDs 47.7 76.0 2.0 0.7 56.9 68.7 34.0 67.2 1.0 1.0 45.8 55.6
ASAS + alt. Buttock 30.8 94.4 5.5 0.7 78.4 94.4 18.1 86.4 1.3 0.9 52.0 56.5
ASAS + NSAIDs 36.9 86.2 2.7 0.7 64.0 67.3 24.4 82.0 1.4 0.9 56.4 61.9
ASAS + stiffness 39.2 81.1 2.1 0.7 58.0 66.8 31.3 76.3 1.3 0.9 51.7 57.7
ASAS + alt. Buttock + NSAIDs 21.5 96.4 6.0 0.8 80.0 64.9 10.7 94.3 1.9 0.9 56.9 94.3
ASAS + stiffness + NSAIDs 28.5 88.8 2.5 0.8 62.7 65.2 19.4 83.1 1.1 1.0 48.3 55.9
ASAS + stiffness + alt. buttock 26.9 94.9 5.3 0.8 77.8 66.2 16.0 88.1 1.3 1.0 52.3 56.3
Other SpA features
Enthesitis 11.5 84.7 0.8 1.0 33.3 59.1 17.8 85.1 1.2 0.9 85.1 45.7
Peripheral arthritis 13.8 90.3 1.4 0.9 48.6 61.2 16.7 87.7 1.4 0.9 87.7 48.9
Dactylitis 23.1 94.4 4.1 0.8 21.4 59.3 4.8 96.9 1.6 09 96.9 52.0
Uveitis 6.2 95.9 1.5 0.9 50.0 60.6 8.1 96.9 2.6 0.9 96.9 64.7
Psoriasis 10.0 88.8 0.9 1.0 37.1 59.8 7.0 83.8 0.4 1.1 83.8 23.5
Inflammatory bowel disease 23.1 96.4 6.4 0.8 30.0 59.8 1.5 94.5 0.3 1.0 94.5 16.0
Family history of SpA 27.7 73.0 1.0 0.9 40.4 60.3 33.7 80.2 1.7 0.8 80.2 54.5
Elevated CRP 40.8 77.5 1.8 0.8 55.1 66.0 38.5 77.1 1.7 0.8 77.1 54.6
HLA-B27 59.7 65.1 1.7 0.6 53.5 70.6 – – – – – –
MRI magnetic resonance imaging, HLA-B27 human leucocyte antigen B27, Sen sensitivity, Spe specificity, LR+ positive likelihood ratio, LR− negative likelihood ratio,
PPV positive predictive value, NPV negative predictive value, ASAS Assessment of SpondyloArthritis International Society, Alt. alternating, NSAIDs nonsteroidal
anti-inflammatory drugs, SpA spondyloarthritis, CRP C-reactive protein
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buttock pain, because of the high cost associated with
MRI-SI: we were searching for a criterion that could help
us in deciding which patients should undergo MRI-SI.
Moreover, the addition of the IBP characteristic of awak-
ening in the second half of the night to the Calin criteria
also increased significantly the likelihood ratio of having a
positive MRI-SI compared to the performance of the Calin
criteria alone (LR+ 5.5 vs 1.8, respectively). Furthermore,
in addition to IBP, other features of SpA have been identi-
fied for predicting the presence of sacroiliitis on MRI in
patients with suspected axSpA. The most useful features
we observed were dactylitis and IBD.
In addition, in order to recommend a tool as diagnos-
tically relevant in the context of a Bayesian approach,
both positive and negative LR should be explored [15]. It
is obvious that single features fall short in this regard.
But if a patient with CBP has any of the four following
characteristics: 1) IBP according to the Calin or ASAS
definition plus alternating buttock pain; 2) IBP according
to the Calin definition plus awakening in the second half
of the night; 3) dactylitis; or 4) IBD, the probability of
having a positive MRI-SI is very high (73–81 %). So in
the case of limited resources, the presence of any of these
three characteristics may help to increase the diagnostic
efficiency of the MRI-SI.
Forecasting a positive HLA-B27 test result is more
difficult: neither the individual IBP characteristics, nor
the existing or other possible combinations were found
useful to predict a positive HLA-B27 test. Among other
SpA features, uveitis appeared to be the most closely
related to a positive HLA-B27, but it is not sufficiently
useful.
To our knowledge, this is the first study investigating
this topic. This study has a few strengths: first, many pa-
tients with suspected axSpA were included from all over
Spain. Second, the mean symptom duration in these pa-
tients was very short compared to most diagnostic utility
studies and this is an advantage in the referral of patients
to early axSpA clinics. Most importantly, patients included
in this analysis came from a national health programme
representing a typical scenario of common clinical prac-
tice that involved primary physicians, rheumatologists and
other specialists who usually take care of patients with
suspected axSpA. Relying on the conclusions of a local
reader (radiologist or rheumatologist) rather than on a re-
port of a central reading committee (as in clinical trials)
should also be interpreted in this context, but this is
exactly the clinical situation that we wanted to address.
Limitations should be considered too: the most import-
ant limitation is the possibility of confounding by indi-
cation. For the analysis of the association between IBP
characteristics, or other features of SpA, and the presence
of sacroiliitis on MRI, data were only included for those pa-
tients in whom MRI-SI was ordered by the rheumatologist.
As there is always a reason to do so, patient selection is
very likely, which may have implications for the external
validity of this study. On the other hand, patients included
in this analysis (because they had MRI ordered) had similar
characteristics to the overall group of patients. Second,
inter-reader variation by 25 different local readers who
assessed the MRI may have influenced this study too. In
this sense, it can be argued that the results of this study are
applicable to clinical practice where many different readers
are usually involved. Third, all patients included in this
study came from the same country and the same cohort,
which may limit the extrapolation of the results to other
countries. However, in a sub-analysis of Spanish patients
participating in the international study evaluating several
referral strategies for diagnosis of axSpA, the national re-
sults were very similar to those observed in the global
population [17]. Fourth, It should be pointed out that the
diagnostic performance is dependent on the prior prob-
ability of the outcome of interest: While the diagnostic
performance in terms of likelihood ratios is considered
to be rather stable across cohorts, the application of these
likelihood ratios in cohorts with other prior probabilities
are very different. A final limitation is obviously that we
failed to frame a group of patients in whom the likelihood
of a positive MRI and/or positive HLAB27 was very low,
as the negative likelihood ratios of all features tested fell
short as the lowest LR− was 0.6.
Conclusions
In summary, if a patient has IBP according to the Calin
or ASAS definition plus alternating buttock pain or IBP
according to the Calin criteria plus awakening in the
second half of the night, or dactylitis or IBD, the prob-
ability of positive MRI-SI increases from 40 to approxi-
mately 75 %. So in the case of limited resources, the
presence of any of these four characteristics may improve
the efficiency of ordering MRI in patients with suspected
axSpA. None of the IBP definitions or any of the other
SpA features appear to be useful to forecasting a positive
HLA-B27 test.
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